氟芬那酸丁酯软膏对特应性皮炎患儿免疫功能指标及生存质量的影响被引量：4

下载PDF

导出

摘要目的分析氟芬那酸丁酯软膏对特应性皮炎患儿免疫功能指标及生存质量的影响。方法收集特应性皮炎患儿100例,随机分为对照组和研究组各50例,对照组予以常规治疗,研究组予以氟芬那酸丁酯软膏治疗,比较治疗后两组患儿免疫球蛋白、T淋巴细胞亚群、生存质量及临床症状变化,临床疗效及不良反应。结果治疗后,研究组免疫球蛋白(IgA、IgG、IgE)优于对照组,比较有显著差异(P<0.05);研究组T淋巴细胞亚群(CD4^+、CD8^+、CD4^+/CD8^+)优于对照组(P<0.05);研究组儿童特应性皮炎影响量表(CADIS)分低于对照组,比较有明显差异(P<0.05);研究组特应性皮炎评分量表(SCORAD)低于对照组(P<0.05);研究组总有效率高于对照组(P<0.05);两组不良反应比较无差异(P>0.05)。结论氟芬那酸丁酯软膏对特应性皮炎患儿的治疗效果确切,能够显著改善患儿的免疫功能与生存质量,值得推广。

作者许文夏云昆王蓓吴恒兰

机构地区武警江苏总队南京医院

出处《贵州医药》 CAS 2017年第7期724-727,共4页 Guizhou Medical Journal

关键词特应性皮炎小儿氟芬那酸丁酯软膏免疫功能生存质量

分类号 R758.2 [医药卫生—皮肤病学与性病学]

引文网络
相关文献

参考文献2

1付桂莉,郑源泉,卢静静,黄美莲.他克莫司治疗儿童特应性皮炎疗效及作用机制研究[J].检验医学与临床,2015,12(4):515-516. 被引量：6
2蔡剑峰,张学奇,邵笑红,吕明芬,李智铭,李秉煦,徐云升.氟芬那酸丁酯软膏治疗儿童特应性皮炎的临床疗效观察[J].中华全科医学,2014,12(8):1214-1215. 被引量：11

二级参考文献26

1Katsunuma T, Tan A, Ohya Y. Short version of a quality-of-life ques- tionnaire in primary caregivers of children with atopic dermatitis ( qp- cad) : development and validation of qp9 [ J ]. Arerugi, 2013,62 ( 1 ) : 33-46.
2Kodani N. The medical good relationship and cooperation between many departments for atopic dermatitis[ J]. Arerugi ,2012,61 ( 12 ) : 1709-1718.
3Kim MS, Hur YG, Kim WG, et al. Inhibitory effect of Platyeodon grandiflorum on Thl and Th2 immune re- sponses in a murine model of 2,4-dinitrofluorobenzene-in- dueed atopie dermatitis-like skin lesions[J]. Ann Allergy Asthma Immunol,2011,106(1) :54-61.
4Park CO, Noh S, Jin S, et al. Insight into newly discovered innate immune modulation in atopic dermatitis[J]. Exp Dermatol. 2 013.2 2 ( 1 ) : 6-9.
5Williams HC,Burney PG, Pembroke AC, et al. Validation of the U. K. diagnostic criteria for atopic dermatitis in a population setting. U. K. Diagnostic Criteria for Atopic Dermatitis Working Party[J]. Br J Dermatol, 1996,135 (1) ~12-17.
6Chamlin SL, Frieden IJ, Williams ML, et al. Effects of atopic dermatitis on young American children and their families[J]. Pediatrics, 2004,114 (3) : 607-611.
7Knol EF, Haeck IM,van Kraats AA, et al. Modulation of lymphocyte function in vivo via inhibition of calcineurin or purine synthesis in patients with atopic dermatitis[J]. J Invest Dermatol~ 2012,132 (10) : 2476-2479.
8Sonkoly E,Janson P,Majuri ML,et al. MiR-155 is over- expressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4~[J]. J Allergy Clin Immu- nol,2010,126(3) .. 581-589.
9Samochocki Z, Alifier M, Bodera P, et al. T-regulatory cells in severe atopic dermatitis:alterations related to cy- tokines and other lymphocyte subpopulations[J]. Arch Dermatol Res,2012,304(10) :795-801.
10Danby SG, Chittock J, Brown K, et al. The effect of ta-crolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis [J]. Br J Dermatol,2014,170(4) :914-921.